Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
46-60 of 4506 results
Oxford BioMedica secures commercial supply licence from UK MHRA
Oxford BioMedica has been granted a Manufacturer/Importer License (MIA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute lentiviral vector material for commercial supply.
Drug Research > Drug Discovery & Development > News
Researchers develop new drug that could treat and limit Parkinson’s disease
Binghamton University researchers have developed a new drug that could possibly limit the progression of Parkinson’s disease and also provide better symptom relief.
Drug Research > Drug Discovery & Development > News
Bristol-Myers Squibb to acquire IFM Therapeutics to expand cancer pipeline
By PBR Staff Writer
Bristol-Myers Squibb has agreed to acquire Boston-based IFM Therapeutics for an upfront payment of $300m to strengthen its oncology pipeline.
Drug Research > Drug Discovery & Development > News
Evotec to acquire Aptuit for $300m
German small molecule drugs developer Evotec has agreed to acquire pharmaceutical services company Aptuit for $300m from private equity firm Welsh, Carson, Anderson & Stowe (WCAS).
Drug Research > Drug Discovery & Development > News
Eagle gets complete response letter from FDA on exertional heat stroke drug RYANODEX
Eagle Pharmaceuticals has received a Complete Response Letter from the US Food and Drug Administration (FDA) for its New Drug Application for RYANODEX (dantrolene sodium) for the treatment of exertional heat stroke (EHS), in conjunction with external cooling methods.
Drug Research > Drug Discovery & Development > News
Evotec, Storm Therapeutics to exploit RNA modulating enzymes for epigenetic drug discovery
Evotec and STORM Therapeutics have expanded their integrated drug discovery collaboration to develop new small molecule epigenetic drugs for oncology and other therapeutic areas.
Drug Research > Drug Discovery & Development > News
GSK to stop 30 drug developments to focus on core therapies
By PBR Staff Writer
GlaxoSmithKline (GSK) has announced its decision to terminate over 30 drug development programs, which it thinks are unlikely to deliver sufficient revenue in the future.
Drug Research > Drug Discovery & Development > News
VenatoRx secures $9.4m to develop new class of antibiotic fro multi-drug resistant bacteria
VenatoRx Pharmaceuticals, which focuses on discovery and development of novel therapies for highly drug resistant bacterial infections, has been awarded up to $9.4m from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator).
Drug Research > Drug Discovery & Development > News
VenatoRx Pharmaceuticals raises $42m in new funding round
VenatoRx Pharmaceuticals has raised $42m in a Series B funding round led by Versant Ventures and joined by Abingworth and Foresite Capital.
Drug Research > Drug Discovery & Development > News
Lilly and Nektar to jointly develop and commercialize autoimmune therapy
Eli Lilly and Company and Nektar Therapeutics have agreed to jointly develop NKTR-358, a novel immunological therapy discovered by the latter.
Drug Research > Drug Discovery & Development > News
Mitsubishi Tanabe to acquire NeuroDerm for $1.1bn
By PBR Staff Writer
Japan-based Mitsubishi Tanabe Pharma (MTPC) has agreed to acquire Israeli drug manufacturer NeuroDerm in an all-cash deal worth $1.1bn.
Drug Research > Drug Discovery & Development > News
UK awards more than £120m for global health research
The UK’s Department of Health has announced that 33 research units and groups will get over £120m funding for global health research.
Drug Research > Drug Discovery & Development > News
Mayo Clinic, nference launch startup company for drug development
By PBR Staff Writer
Mayo Clinic and nference have jointly formed a new startup to discover and develop therapies for diseases with unmet medical need using artificial intelligence (AI).
Drug Research > Drug Discovery & Development > News
Biognosys raises new funds to bring Proteomics to life science research market
Proteomics firm Biognosys has secured $5m funding from new and existing investors in an extended series C round.
Drug Research > Drug Discovery & Development > News
Celgene, BeiGene to advance PD-1 inhibitor for solid tumor cancers
By PBR Staff Writer
Celgene has agreed to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317 for the treatment of solid tumor cancers.
Drug Research > Drug Discovery & Development > News
46-60 of 4506 results